Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Smruthi Vijayaraghavan, Cansu Karakaş, Iman Doostan, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 246

Showing 76-100 of 246 citing articles:

Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies
Joseph A. Caruso, MyLinh Duong, Jason P.W. Carey, et al.
Cancer Research (2018) Vol. 78, Iss. 19, pp. 5481-5491
Open Access | Times Cited: 50
Novel circular RNA, hsa_circ_0025039 promotes cell growth, invasion and glucose metabolism in malignant melanoma via the miR-198/CDK4 axis
Donghui Bian, Yan Wu, Guodong Song
Biomedicine & Pharmacotherapy (2018) Vol. 108, pp. 165-176
Open Access | Times Cited: 50
The Role of CDK4/6 Inhibitors in Breast Cancer
Conleth G. Murphy
Current Treatment Options in Oncology (2019) Vol. 20, Iss. 6
Open Access | Times Cited: 48
Autophagy modulation altered differentiation capacity of CD146+ cells toward endothelial cells, pericytes, and cardiomyocytes
Mehdi Hassanpour, Jafar Rezaie, Masoud Darabi, et al.
Stem Cell Research & Therapy (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 48
PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer
Kristen Wong, Francesca Di Cristofano, Michela Ranieri, et al.
Endocrine Related Cancer (2019) Vol. 26, Iss. 4, pp. 425-436
Open Access | Times Cited: 43
circACTA2 mediates Ang II-induced VSMC senescence by modulation of the interaction of ILF3 with CDK4 mRNA
Ying Ma, Bin Zheng, Xinhua Zhang, et al.
Aging (2021) Vol. 13, Iss. 8, pp. 11610-11628
Open Access | Times Cited: 35
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
Santiago Duro‐Sánchez, Mercedes Nadal‐Serrano, Marta Lalinde-Gutiérrez, et al.
Cancer Research (2022) Vol. 82, Iss. 24, pp. 4670-4679
Open Access | Times Cited: 28
Targeting CDK4/6 for Anticancer Therapy
Jiating Qi, Zhuqing Ouyang
Biomedicines (2022) Vol. 10, Iss. 3, pp. 685-685
Open Access | Times Cited: 23
LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein
Zijie Cai, Qianfeng Shi, Yudong Li, et al.
Science Advances (2023) Vol. 9, Iss. 40
Open Access | Times Cited: 16
The Role of Autophagy in Breast Cancer Metastasis
Hye Min Kim, Ja Seung Koo
Biomedicines (2023) Vol. 11, Iss. 2, pp. 618-618
Open Access | Times Cited: 14
A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy
Mohammed El‐Sadoni, Sofian Al Shboul, Ahmad Alhesa, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 91, Iss. 4, pp. 345-360
Closed Access | Times Cited: 14
Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma
Anthony M. Robinson, Richa Rathore, Nathan Redlich, et al.
Cell Death and Disease (2019) Vol. 10, Iss. 11
Open Access | Times Cited: 41
CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
Priya Gopalan, Andres Gordillo Villegas, Chunxia Cao, et al.
Oncotarget (2018) Vol. 9, Iss. 100, pp. 37352-37366
Open Access | Times Cited: 40
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs
Jennifer L. Green, Eric Okerberg, Josilyn Sejd, et al.
Molecular Cancer Therapeutics (2019) Vol. 18, Iss. 4, pp. 771-779
Closed Access | Times Cited: 38
eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
Tim Kong, Yibo Xue, Regina Cencic, et al.
Molecular Cancer Therapeutics (2019) Vol. 18, Iss. 11, pp. 2158-2170
Open Access | Times Cited: 37
Roles of autophagy in breast cancer treatment: Target, bystander or benefactor
Liliya Tyutyunyk‐Massey, David A. Gewirtz
Seminars in Cancer Biology (2019) Vol. 66, pp. 155-162
Closed Access | Times Cited: 37
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?
Christin Riess, Nina Irmscher, Inken Salewski, et al.
Cancer and Metastasis Reviews (2020) Vol. 40, Iss. 1, pp. 153-171
Open Access | Times Cited: 35
Cellular senescence: from anti-cancer weapon to anti-aging target
Lifeng Yuan, Peter B. Alexander, Xiao‐Fan Wang
Science China Life Sciences (2020) Vol. 63, Iss. 3, pp. 332-342
Closed Access | Times Cited: 34
Autophagy regulation as a promising approach for improving cancer immunotherapy
Nestor Ishimwe, Wenbin Zhang, Jieying Qian, et al.
Cancer Letters (2020) Vol. 475, pp. 34-42
Closed Access | Times Cited: 33
MicroRNAs are critical regulators of senescence and aging in mesenchymal stem cells
Matthew L. Potter, William Hill, Carlos M. Isales, et al.
Bone (2020) Vol. 142, pp. 115679-115679
Open Access | Times Cited: 33
Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells
Hillary H. Le, Süleyman Selim Çınaroğlu, Elise C. Manalo, et al.
EBioMedicine (2021) Vol. 73, pp. 103646-103646
Open Access | Times Cited: 32
Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline
Deendyal Bhurta, Sandip B. Bharate
Medicinal Research Reviews (2021) Vol. 42, Iss. 2, pp. 654-709
Closed Access | Times Cited: 31
A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer
Shidi Zhao, Haochen Zhang, Na Yang, et al.
Translational Cancer Research (2023) Vol. 12, Iss. 6, pp. 1617-1634
Open Access | Times Cited: 12
Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Wen‐Ting Peng, Xi Jin, Xiao‐En Xu, et al.
Cancer Research (2023) Vol. 83, Iss. 10, pp. 1711-1724
Open Access | Times Cited: 11
Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy
Rosalba Torrisi, Valentina Vaira, Laura Giordano, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1498-1498
Open Access | Times Cited: 4

Scroll to top